In Vitro Pharmacodynamics and Bactericidal Mechanism of Fungal Defensin-Derived Peptides NZX and P2 Against

Overview

Journal Microorganisms

Specialty Microbiology

Date 2022 May 28

PMID 35630326

Authors

Yankang Wu

Na Yang

Ruoyu Mao

Ya Hao

Da Teng

Jianhua Wang

Affiliations

Soon will be listed here.

Abstract

(1) Background: Based on the hazard of to human and animal health and the increasing drug resistance, it is urgent to develop new antimicrobial agents with high bactericidal activity and low drug resistance against . This study aims to investigate in vitro pharmacodynamics and bactericidal mechanism of fungal defensin-derived peptides NZX and P2 against . (2) Methods: Minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC) were determined by broth dilution method and AGAR plate dilution method. Cell membrane integrity was determined by flow cytometer. Cell morphological changes were observed by scanning electron microscope (SEM) and transmission electron microscope (TEM). (3) Results: MIC values (NZX: 0.11 μM, P2: 0.91 μM) and MPC (NZX: 1.82 μM) showed their higher antibacterial activity and stronger inhibition ability of drug resistance mutation. The bactericidal mechanism was elucidated that P2 caused ACCC 61733 cells to deform, bound to the cell wall, and perturbed cell membrane, resulting in K leakage, membrane hyperpolarization, ATP release, and reduced cell contents. Compared with P2, NZX focuses on the cell wall, and it bound to the cell wall causing cells boundary disappearance. (4) Conclusion: NZX and P2 are promising antimicrobial agents for streptococcicosis treatment.

Citing Articles

Self-Assembled Peptide Hydrogels PPI45 and PPI47: Novel Drug Candidates for Infection Treatment.

Wu Q, Deng M, Mao R, Yang N, Hao Y, Cao M Gels. 2025; 11(1).

PMID: 39852034 PMC: 11764660. DOI: 10.3390/gels11010063.

Evaluation of the activity of antimicrobial peptides against bacterial vaginosis.

Kang X, Zhao T, Song Y, Zhang J, Yuan T, Han Q Open Life Sci. 2024; 19(1):20220927.

PMID: 39091626 PMC: 11292031. DOI: 10.1515/biol-2022-0927.

Antibacterial activity and mechanism of chelerythrine against .

Xin J, Pu Q, Wang R, Gu Y, He L, Du X Front Vet Sci. 2024; 11:1408376.

PMID: 38948675 PMC: 11212505. DOI: 10.3389/fvets.2024.1408376.

In Vitro/Vivo Mechanisms of Antibacterial Peptide NZ2114 against and Its Biofilms.

Zhang S, Yang N, Mao R, Hao Y, Teng D, Wang J Antibiotics (Basel). 2024; 13(4).

PMID: 38667017 PMC: 11047522. DOI: 10.3390/antibiotics13040341.

Pharmacokinetics and pharmacodynamics of antibacterial peptide NZX in Staphylococcus aureus mastitis mouse model.

Zheng X, Yang N, Mao R, Hao Y, Teng D, Wang J Appl Microbiol Biotechnol. 2024; 108(1):260.

PMID: 38472422 PMC: 11636681. DOI: 10.1007/s00253-024-13101-w.

References

Gao J, Yu F, Luo L, He J, Hou R, Zhang H . Antibiotic resistance of Streptococcus agalactiae from cows with mastitis. Vet J. 2012; 194(3):423-4. DOI: 10.1016/j.tvjl.2012.04.020. View

Drlica K, Zhao X . Mutant selection window hypothesis updated. Clin Infect Dis. 2007; 44(5):681-8. DOI: 10.1086/511642. View

Chu C, Huang P, Chen H, Wang Y, Tsai I, Lu C . Genetic and pathogenic difference between Streptococcus agalactiae serotype Ia fish and human isolates. BMC Microbiol. 2016; 16(1):175. PMC: 4971743. DOI: 10.1186/s12866-016-0794-4. View

Kaminska D, Ratajczak M, Szumala-Kakol A, Dlugaszewska J, Nowak-Malczewska D, Gajecka M . Increasing Resistance and Changes in Distribution of Serotypes of in Poland. Pathogens. 2020; 9(7). PMC: 7400139. DOI: 10.3390/pathogens9070526. View

Li W, OBrien-Simpson N, Tailhades J, Pantarat N, Dawson R, Otvos Jr L . Multimerization of a Proline-Rich Antimicrobial Peptide, Chex-Arg20, Alters Its Mechanism of Interaction with the Escherichia coli Membrane. Chem Biol. 2015; 22(9):1250-8. DOI: 10.1016/j.chembiol.2015.08.011. View

Ahn K, Kim A, Kum K, Yun C, Han S . The synthetic human beta-defensin-3 C15 peptide exhibits antimicrobial activity against Streptococcus mutans, both alone and in combination with dental disinfectants. J Microbiol. 2017; 55(10):830-836. DOI: 10.1007/s12275-017-7362-y. View

Campbell J, Hillier S, Krohn M, Ferrieri P, Zaleznik D, Baker C . Group B streptococcal colonization and serotype-specific immunity in pregnant women at delivery. Obstet Gynecol. 2000; 96(4):498-503. DOI: 10.1016/s0029-7844(00)00977-7. View

Tenland E, Krishnan N, Ronnholm A, Kalsum S, Puthia M, Morgelin M . A novel derivative of the fungal antimicrobial peptide plectasin is active against Mycobacterium tuberculosis. Tuberculosis (Edinb). 2018; 113:231-238. PMC: 6289163. DOI: 10.1016/j.tube.2018.10.008. View

Guilhelmelli F, Vilela N, Albuquerque P, Derengowski L, Silva-Pereira I, Kyaw C . Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. Front Microbiol. 2013; 4:353. PMC: 3856679. DOI: 10.3389/fmicb.2013.00353. View

10.

Lunde C, Hartouni S, Janc J, Mammen M, Humphrey P, Benton B . Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother. 2009; 53(8):3375-83. PMC: 2715647. DOI: 10.1128/AAC.01710-08. View

11.

Joshi R, Skaaurd A, Alvarez A . Experimental validation of genetic selection for resistance against Streptococcus agalactiae via different routes of infection in the commercial Nile tilapia breeding programme. J Anim Breed Genet. 2020; 138(3):338-348. DOI: 10.1111/jbg.12516. View

12.

Maisey H, Doran K, Nizet V . Recent advances in understanding the molecular basis of group B Streptococcus virulence. Expert Rev Mol Med. 2008; 10:e27. PMC: 2676346. DOI: 10.1017/S1462399408000811. View

13.

Ma Z, Yang J, Han J, Gao L, Liu H, Lu Z . Insights into the Antimicrobial Activity and Cytotoxicity of Engineered α-Helical Peptide Amphiphiles. J Med Chem. 2016; 59(24):10946-10962. DOI: 10.1021/acs.jmedchem.6b00922. View

14.

Cunha E, Janela R, Costa M, Tavares L, Veiga A, Oliveira M . Nisin Influence on the Antimicrobial Resistance Ability of Canine Oral Enterococci. Antibiotics (Basel). 2020; 9(12). PMC: 7763880. DOI: 10.3390/antibiotics9120890. View

15.

Schneider T, Kruse T, Wimmer R, Wiedemann I, Sass V, Pag U . Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science. 2010; 328(5982):1168-72. DOI: 10.1126/science.1185723. View

16.

Munch D, Sahl H . Structural variations of the cell wall precursor lipid II in Gram-positive bacteria - Impact on binding and efficacy of antimicrobial peptides. Biochim Biophys Acta. 2015; 1848(11 Pt B):3062-71. DOI: 10.1016/j.bbamem.2015.04.014. View

17.

Shan Y, Yang N, Teng D, Wang X, Mao R, Hao Y . Recombinant of the Staphylococcal Bacteriophage Lysin CHAP and Its Elimination against Biofilms. Microorganisms. 2020; 8(2). PMC: 7074704. DOI: 10.3390/microorganisms8020216. View

18.

Cao X, Zhang Y, Mao R, Teng D, Wang X, Wang J . Design and recombination expression of a novel plectasin-derived peptide MP1106 and its properties against Staphylococcus aureus. Appl Microbiol Biotechnol. 2014; 99(6):2649-62. DOI: 10.1007/s00253-014-6077-9. View

19.

Hara S, Mukae H, Sakamoto N, Ishimoto H, Amenomori M, Fujita H . Plectasin has antibacterial activity and no affect on cell viability or IL-8 production. Biochem Biophys Res Commun. 2008; 374(4):709-13. DOI: 10.1016/j.bbrc.2008.07.093. View

20.

Porto W, Irazazabal L, Alves E, Ribeiro S, Matos C, Pires A . In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design. Nat Commun. 2018; 9(1):1490. PMC: 5902452. DOI: 10.1038/s41467-018-03746-3. View